Kramer CK, Choi H, Zinman B, Retnakaran R. Determinants of reversibility of ␤-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes. Am J Physiol Endocrinol Metab 305: E1398 -E1407, 2013. First published October 15, 2013 doi:10.1152/ajpendo.00447.2013.-Short-term intensive insulin therapy (IIT) can improve pancreatic ␤-cell function when administered early in the course of type 2 diabetes mellitus (T2DM). However, the degree of improvement in response to this therapy varies between patients. Thus, we sought to characterize the determinants of improvement in ␤-cell function in response to short-term IIT in early T2DM. Sixty-three patients with mean 3.0 Ϯ 2.1 yr duration of T2DM and Hb A 1c of 6.8 Ϯ 0.8% underwent 4 wk of IIT consisting of basal insulin detemir and premeal insulin aspart, with oral glucose tolerance test administered at baseline and 1 day post-IIT. ␤-Cell function before and after IIT was assessed by Insulin Secretion Sensitivity Index-2 (ISSI-2). Reversibility of ␤-cell dysfunction was defined as percentage change in ISSI-2 of Ն25%. Overall, the study population experienced an increase in ISSI-2 from baseline to post-IIT (P ϭ 0.01), with one-third of participants achieving Ն25% improvement in ISSI-2. Compared with their peers, those with increases in ISSI-2 of Ն25% had greater decrements in fasting glucose (P Ͻ 0.0001), Hb A 1c (P ϭ 0.001), ALT (P ϭ 0.04), AST (P ϭ 0.02), and HOMA-IR (P Ͻ 0.0001). On logistical regression analysis, baseline Hb A 1c (OR ϭ 2.83, 95% CI 1.16 -6.88, P ϭ 0.02) and change in HOMA-IR (OR ϭ 0.008, 95%CI 0.0004 -0.16, P ϭ 0.001) emerged as independent predictors of reversibility of ␤-cell dysfunction. Indeed, reversibility of ␤-cell dysfunction was achieved in only those participants in whom IIT yielded an improvement in HOMA-IR. In conclusion, decline in HOMA-IR may be a key determinant of improvement of ␤-cell function in response to short-term IIT, suggesting a fundamental contribution of insulin resistance to the reversible component of ␤-cell dysfunction in early T2DM.
intensive insulin therapy; type 2 diabetes; ␤-cell function; insulin resistance; remission THE NATURAL HISTORY OF TYPE 2 DIABETES MELLITUS (T2DM) is characterized by the progressive deterioration of pancreatic ␤-cell function over time, a pathological process that occurs irrespective of lifestyle and current pharmacological interventions (13, 32) . In recent years, however, several studies have shown that temporary administration of short-term intensive insulin therapy (IIT) early in the course of T2DM can improve ␤-cell function and insulin resistance (4 -6, 17, 33) . Indeed, this 2-to 4-wk treatment can induce a "glycemic remission," wherein patients are subsequently able to maintain euglycemia without antidiabetic medications for up to 2 yr (15, 22, 25, 31) .
These promising effects were recently confirmed in a metaanalysis of seven studies involving Asian populations (15) , which highlighted the potential of this treatment strategy and also the need for studies across ethnic groups (7) .
It is important to recognize that the ␤-cell response to short-term IIT is heterogeneous (29) , possibly reflecting the varying contributions of different pathological mechanisms to the insulin secretory dysfunction observed in T2DM. Indeed, the progressive deterioration of ␤-cell function that characterizes the natural history of T2DM consists of both a presumed irreversible component (such as loss of ␤-cell mass through apoptosis) and a reversible element resulting from the deleterious effect of hyperglycemia on ␤-cell secretory capacity, a phenomenon called "glucotoxicity" (31) . Unfortunately, however, current measurements of ␤-cell function cannot distinguish the relative contributions of these two components. In this context, the elucidation of predictors of the reversibility of ␤-cell dysfunction in response to short-term IIT could provide insight relevant to both 1) the identification of those patients that are most likely to respond favorably to this therapy and 2) the pathophysiological basis underlying this response. Thus, the aim of this study was to characterize the determinants and mechanisms underlying reversibility of ␤-cell dysfunction in response to short-term IIT in a multiethnic population of patients with early T2DM.
METHODS

Study population.
The study population consisted of 63 adult patients with T2DM who underwent a short course of IIT to determine eligibility for a clinical trial (NCT01270789; ClinicalTrials.Gov). Inclusion criteria included 1) duration of diabetes Յ7 yr, 2) treatment with zero to two oral antidiabetic medications, and 3) hemoglobin A 1c (Hb A1c) at screening between 5.5 and 9.0% inclusive if on oral antidiabetic medications or between 6.0 and 10.0% inclusive if not on antidiabetic medications. Exclusion criteria included current insulin therapy, renal dysfunction, hepatic dysfunction, malignancy, and chronic infection. The study protocol was approved by the Mount Sinai Hospital Research Ethics Board, and all participants provided written informed consent.
Study design. At the outset of the study, the 63 participants stopped all antidiabetic medications (metformin or sulfonylurea; there were no subjects on thiazolidinediones, dipeptidyl peptidase IV inhibitors, or GLP-1 agonists). The next day, they underwent a 2-h, 75-g oral glucose tolerance test (OGTT) that was performed the morning after overnight fast. Following the initial OGTT, the participants underwent a 4-wk course of multiple daily insulin injection therapy consisting of basal insulin detemir and premeal insulin aspart, with starting total daily doses of 0.2-0.4 U/kg, divided as 60% bolus insulin and 40% basal insulin. Participants were asked to perform self-monitoring of capillary blood glucose (SMBG) at least four times/day, including 1) fasting glucose daily, 2) premeal glucose at breakfast, lunch, and dinner at least four times/wk (each), 3) 2-h postprandial glucose after breakfast, lunch, and dinner at least four times/wk (each), and 4) bedtime (Ն4 times/wk) and to send their SMBG records to the study nurse at least three times/wk for insulin dose titration. Insulin doses were titrated to target fasting glucose between 4.0 and 6.0 mmol/l and at 2-h postprandial glucose Ͻ8 mmol/l. Insulin therapy was administered for 4 wk but was extended Յ5-6 wk in 19 participants (generally due to patient scheduling issues). Hypoglycemia was defined as capillary blood glucose Յ3.9 mmol/l and was classified as severe if it required third party assistance and/or involved impairment of consciousness.
On the final day of IIT, the last insulin dose was the bolus insulin before dinner, with no bedtime basal insulin. A 2-h OGTT was performed the day after cessation of IIT (off all antidiabetic therapy), using the same protocol as at baseline (and performed in the morning after overnight fast).
Laboratory measurements. During each OGTT, venous blood samples were drawn for the measurement of glucose, C-peptide, and insulin at fasting and at 30, 60, 90, and 120 min following ingestion of the 75-g glucose load. Specific insulin levels were measured with Roche-Elecsys-1010 immunoassay analyzer and electrochemiluminescence immunoassay kit (Roche Diagnostics, Laval, QC, Canada). C-peptide was measured using the Roche Modular system and electrochemiluminescence immunoassay kit (Roche Diagnostics).
Area under the insulin curve (AUCins) and area under the glucose curve (AUC gluc) during the OGTT were calculated using the trapezoidal rule. ␤-Cell function was assessed on each OGTT with the Insulin Secretion Sensitivity Index-2 (ISSI-2). ISSI-2 is a validated OGTT-derived measurement of ␤-cell function that is analogous to the disposition index obtained from the intravenous glucose tolerance test (IVGTT) (26, 27) . ISSI-2 has been validated directly against the disposition index from the IVGTT, with which it exhibits stronger correlation than other OGTT-derived measurements of ␤-cell function (including insulinogenic index-based measures and the homeostasis model assessment of ␤-cell function) (27) and has been used to measure ␤-cell function in several previous studies, including both clinical trials and observational studies (14, 23, 28, 30, 34) . ISSI-2 is defined as the product of 1) insulin secretion measured by the ratio of AUCins to AUCgluc and 2) insulin sensitivity measured by the Matsuda index (26) . The Matsuda index is a validated measurement of whole body insulin sensitivity (21) . Insulin resistance (primarily hepatic) was assessed by the homeostasis model assessment of insulin resistance (HOMA-IR) (20) .
Statistical analyses. All analyses were conducted using SPSS 18.0 (Chicago, IL). Continuous variables were tested for normality of distribution, and natural log transformations of skewed variables were used where necessary. Variables with normal distribution are presented as means Ϯ SD, and those with nonnormal distribution are presented as median (25th-75th percentile). Using participants' SMBG data, we determined the weekly mean capillary glucose values in the cohort before and 2 h after breakfast, lunch, and dinner and compared the mean daily capillary glucose profiles over time on IIT (week 1-4) by analysis of variance for repeated measurements (Fig. 1) .
We defined an increase in ISSI-2 of Ն25% after IIT (compared with baseline) as a threshold indicative of significant reversibility of ␤-cell dysfunction. We applied this threshold because a 25% improvement in ␤-cell function would represent a very robust change in 4 wk, particularly since a previous study (18) reported that, in response to short-term IIT, patients who achieved glycemic remission had a 16% greater increase in ␤-cell function than those who did not achieve remission. Based on this ISSI-2 increment, participants were then stratified into two groups: those with reversibility of ␤-cell dysfunction (change in ISSI-2 Ն25%) and those without (change in ISSI-2 Ͻ25%). The characteristics of these two groups were compared by Student's t-test (continuous variables) or either chi-square or Fisher exact test (categorical variables) ( Table 1) . Univariate associations between the percentage change in ISSI-2 and potential determinants were assessed by Spearman correlation analysis ( Table 2) .
Multiple linear regression analyses of percentage change in ISSI-2 (dependent variable) were performed with a core model consisting of the following variables: age, ethnicity, duration of diabetes, and baseline BMI (Table 3) . Exploratory multiple linear regression analyses were performed with single addition of the following covariates: Hb A1c, HOMA-IR, alanine aminotransferase (ALT), and Matsuda index. For each of these variables, we evaluated both the baseline measurement (i.e., potential determinants of ␤-cell function reversibility) and the change in response to IIT (i.e., potential mechanisms).
To further evaluate the determinants and mechanisms of ␤-cell dysfunction reversibility, logistic regression analyses were performed, with an ISSI-2 increment of Ն25% as the outcome. The independent variables included in the core model were age, ethnicity, duration of diabetes, and baseline BMI. Exploratory models were then constructed the same way as that described above ( Table 4 ). The goodness of fit of the models was assessed by Hosmer and Lemeshow test (all P values nonsignificant) (11) . In addition, sensitivity analyses were performed using different thresholds for the ISSI-2 increment (Ն10, Ն15, Ն20, Ն30, and Ն35%).
RESULTS
The study population consisted of 63 participants (40 males, 46 patients of white ethnicity) with a mean age of 59 Ϯ 8.2 yr and duration of diabetes of 3.0 Ϯ 2.1 yr. During the 4 wk of IIT, the rate of hypoglycemic events was [median (25th-75th percentile)] 0.20 (0.0 -0.62) per person per year, and there were no severe episodes. Figure 1 shows the mean daily capillary glucose profile by week on IIT; as expected, there was a progressive decrease in glucose values over the 4 wk on insulin treatment (P Ͻ 0.001). As expected in patients with established diabetes of mean 3.0 yr duration, overall glucose tolerance was not improved after 4 wk of IIT (P ϭ 0.1). However, after the IIT, there was an overall improvement in ␤-cell function, as reflected in a significant increment in ISSI-2 from baseline to post-IIT [median 183 (121-233) vs. 190 (142-289), P ϭ 0.01] in the range that would be expected in patients with T2DM [e.g., as opposed to ISSI-2 values Ͼ800, as generally observed in healthy individuals (28)]. A significant improvement was similarly seen in the 46 white patients (P ϭ 0.037). Overall, the mean percentage increase in ISSI-2 in the study population was 25%.
To elucidate determinants of reversibility of ␤-cell dysfunction, we stratified participants into 1) those in whom IIT induced an increase in ISSI-2 of Ն25% (n ϭ 21; one-third of Continued the study population) and 2) those in whom it did not yield such a large improvement (n ϭ 42). As shown in Table 1 In addition, they had higher baseline ALT and aspartate aminotransferase (AST) at borderline significance (P ϭ 0.05 and P ϭ 0.06, respectively). The two groups received similar insulin dosages (initial and final) and did not differ with respect to changes in BMI or waist. Of note, participants with percentage change in ISSI-2 of Ն25% had significantly higher decrements in fasting glucose (P Ͻ 0.0001), Hb A 1c (P ϭ 0.001), ALT (P ϭ 0.04), and AST (P ϭ 0.02) compared with those with a change in ISSI-2 of Ͻ25%. Moreover, these participants had a significant improvement in insulin resistance compared with those with lesser change in ISSI-2 [change in HOMA-IR: Ϫ0.7 (Ϫ1.1 to Ϫ0.5) vs. Ϫ0.1 (Ϫ0.3 to 0.20), P Ͻ 0.0001]; this differential improvement was also evident when the change in Matsuda index (P Ͻ 0.0001) was compared between the groups. Figure 2 shows the glucose, insulin, and C-peptide responses to the OGTT in the two groups. On Spearman correlation analysis (Table 2) , the percentage change in ISSI-2 was positively associated with the following baseline covariates: fasting plasma glucose (r ϭ 0.41, P ϭ 0.001), Hb A 1c (r ϭ 0.50, P Ͻ 0.0001), and HOMA-IR (r ϭ 0.26, P ϭ 0.04). Furthermore, the percentage change in ISSI-2 was strongly correlated with the changes in insulin sensitivity/ resistance and glycemia following IIT. Specifically, it was positively associated with the change in Matsuda index of insulin sensitivity (r ϭ 0.51, P Ͻ 0.0001) and negatively associated with the changes in HOMA-IR (r ϭ Ϫ0.72, P Ͻ 0.0001) and Hb A 1c (rϭϪ0.46, P Ͻ 0.0001). None of the other clinical characteristics was associated with the percentage change in ISSI-2.
We next performed multiple linear regression analyses of dependent variable percentage change in ISSI-2 to identify independent determinants of this change (Table 3) . On these analyses, baseline Hb A 1c and change in HOMA-IR were independently associated with the change in ISSI-2 in all adjusted models. In the fully adjusted model (model 10), baseline Hb A 1c was a positive predictor of the percentage change in ISSI-2 (standardized ␤ ϭ 0.51, P Ͻ 0.0001) whereas the change in HOMA-IR had a negative association (standardized ␤ ϭ Ϫ0.47, P Ͻ 0.0001); the additional covariates age, ethnicity, duration of diabetes, and baseline BMI were not significant predictors. Of note, this model achieved an adjusted r 2 of 0.70. The results were unchanged with either 1) inclusion of previous use of oral antidiabetic medications as a covariate in the model or 2) calculation of ISSI-2 with area under the C-peptide curve instead of AUC ins (data not shown). Baseline ALT was associated with change in ISSI-2 in a model adjusted for core variables; however, when further adjusted for baseline Hb A 1c , it was no longer significant (Table 3) . To further evaluate the determinants and mechanisms of reversibility of ␤-cell dysfunction, we performed logistical regression analyses with a change in ISSI-2 of Ն25% as the dependent variable. These analyses showed that baseline Hb A 1c and change in HOMA-IR were independently associated with reversibility of ␤-cell dysfunction (Table 4) . Indeed, in a model adjusted for age, ethnicity, duration of diabetes, and baseline BMI, both baseline Hb A 1c (OR ϭ 2.83, 95% CI 1.16 -6.88, P ϭ 0.02) and change in HOMA-IR (OR ϭ 0.008, 95%CI 0.0004 -0.16, P ϭ 0.001) were associated with reversibility of ␤-cell dysfunction (model 10; Table 4 ). The same two factors (baseline Hb A 1c and change in HOMA-IR) also Continuous data presented as means Ϯ SD (if normally distributed) or median followed by 25th-75th percentile (if skewed). ISSI-2, Insulin Secretion Sensitivity Index-2; IIT, intensive insulin therapy; ALT, alanine aminotransferase; HOMA-IR, homeostasis model assessment of insulin resistance. emerged as the only significant independent predictors when the analysis was restricted to white participants only (data not shown). In addition, the results were unchanged in sensitivity analyses in which the logistical regression analyses (model 10) were repeated using different thresholds to define significant change in ISSI-2 (Ն10, Ն15, Ն20, Ն30, and Ն35%; data not shown).
Having identified change in HOMA-IR as an independent determinant of the reversibility of ␤-cell dysfunction in all adjusted analyses, we evaluated the distribution of percentage change in ISSI-2 in relation to the change in HOMA-IR. Interestingly, as shown in Fig. 3 , all participants with change in ISSI-2 of Ն25% had a decrement in HOMA-IR. In other words, only those participants in whom IIT yielded an improvement in HOMA-IR achieved significant reversibility of ␤-cell dysfunction.
DISCUSSION
In this study, we demonstrate that a short course of IIT can safely improve ␤-cell function in a multiethnic population of patients with well-controlled, recently diagnosed T2DM. In one-third of participants, this treatment improved ␤-cell function by at least 25% and was accompanied by lowering of glycemia, liver enzymes, and insulin resistance. Furthermore, baseline Hb A 1c and improvement in insulin resistance emerged as independent determinants of this reversibility of ␤-cell dysfunction, yielding insight relevant to both the identification of patients who are most likely to respond in this way and the pathophysiology underlying this effect.
The natural history of T2DM is characterized by the progressive decline of ␤-cell function over time accompanied by rising glycemia. Although part of this deterioration is due to the presumably irreversible loss of ␤-cell mass, it should be recognized that the resultant glycemia itself has deleterious effects on insulin secretion (i.e., glucotoxicity). Indeed, firstphase insulin secretion is abolished at a blood glucose level of 6.4 mmol/l (3). This glucotoxic effect holds two important implications. First, ␤-cell dysfunction early in the course of T2DM should have a reversible component secondary to glucotoxicity. Second, this glucotoxicity should cause an amplification of hyperglycemia for the degree of underlying ␤-cell pathology.
The response to short-term IIT in the current study provides support for this model. First, reversibility of ␤-cell dysfunction was apparent in the overall increase in ISSI-2 after short-term IIT and particularly in the marked improvement observed in one-third of the study population. Second, the amplification of hyperglycemia by this reversible ␤-cell dysfunction is consis- tent with the finding that the latter group had higher baseline Hb A 1c than the other participants (median 7.2 vs. 6.5%) despite similar duration of diabetes and no other differences in baseline clinical characteristics. In other words, their poorer glycemic control at baseline in the setting of similar disease duration may have reflected a more pronounced effect of glucotoxicity, and as such, these participants had the greatest improvement in ␤-cell function in response to IIT. Indeed, although the study population had very good glycemic control overall at the outset (mean Hb A 1c 6.8%), baseline Hb A 1c was an independent predictor of reversibility. Thus, a key finding from these data is that higher baseline glycemia may predict reversibility of ␤-cell dysfunction if glucotoxicity is contributing to the hyperglycemia. Although glucotoxicity may be a feature of those participants whose ␤-cell dysfunction is most likely to respond to IIT, we demonstrate that the key determinant of this response was the improvement in insulin resistance. The concept that insulin treatment can reduce insulin resistance has been recognized since the 1980s (9, 10) . More recently, a beneficial effect of short-term IIT on insulin resistance, as assessed by HOMA-IR, has been demonstrated in several interventional studies (4 -6, 17, 33) and a meta-analysis (15) . These reports, however, did not evaluate the potential impact of this improvement in insulin resistance on the ␤-cell functional response to IIT.
It is known that insulin therapy can improve insulin sensitivity at both skeletal muscle and liver (1, 12) , where its effects include suppression of hepatic gluconeogenesis and reduction of liver fat content. The current study suggests that the hepatic effects may be particularly relevant to the reversibility of ␤-cell dysfunction. Indeed, the percentage change in ISSI-2 was more strongly correlated with the change in HOMA-IR (r ϭ Ϫ0.72, P Ͻ 0.0001), which primarily reflects hepatic insulin resistance, than with the change in the Matsuda index of whole body insulin sensitivity (r ϭ 0.51, P Ͻ 0.0001). Moreover, only those participants in whom IIT yielded an improvement in HOMA-IR achieved reversibility of ␤-cell dysfunction. Finally, the participants in whom IIT increased ISSI-2 by Ն25% achieved significantly greater decrements in ALT and AST than did their peers, again potentially implicating effects on the liver. Taken together, these data raise the possibility that the change in HOMA-IR (or possibly another hepatic marker) in response to short-term IIT may provide a means of identifying those patients that are most likely to benefit from this therapy.
Although clearly important, the elimination of glucotoxicity and improvement of insulin resistance may not be the sole bases for the improvement in ␤-cell function achieved with short-term IIT early in the course of T2DM. Noteworthy in this regard is the study by Weng et al. (33) in which 382 patients with recently diagnosed T2DM were randomized to 2-5 wk of treatment with IIT or oral antidiabetic medications. In this study, insulin therapy was associated with significantly higher rates of remission and preservation of first-phase insulin secretion after 1 yr compared with oral antidiabetic medications (33) . These apparent beneficial effects of insulin, compared with oral medications, suggest that the relevant mechanisms underlying long-term improvement in ␤-cell function likely extend beyond glucose lowering alone. This concept is further supported by studies showing that preceding exposure to exogenous insulin can enhance glucose-stimulated insulin secretion in healthy individuals (2, 19) . Coupled with evidence that islet cells express insulin receptors and signaling proteins whose disruption can lead to defective glucose metabolism in animal models (8, 16) , these data support an important physiological role for insulin signaling in the ␤-cell, which may potentially be relevant to the improvement in ␤-cell function that can be achieved with early short-term IIT.
This study also highlights the feasibility of administering short-term IIT early in T2DM. As shown in Fig. 1 , the study population had tight glycemic control while receiving IIT (e.g., mean 2-h postprandial capillary glucose levels in week 1 were Ͻ8.0 mmol/l and still improved further in weeks [2] [3] [4] . Despite this tight glycemic control, participants had very low rates of any hypoglycemia, even with the very liberal definition (blood glucose Յ3.9 mmol/l) used in this study. This capacity to achieve tight glycemic control without excessive hypoglycemia likely reflects the moderating contribution of endogenous insulin secretion (resulting from the reversibility of ␤-cell dysfunction), a supposition that is supported by the fact that the final IIT doses were lower than those that would be expected for full insulin replacement in patients with long-standing T2DM and BMI of ϳ30 kg/m 2 ( Table 1 ). In addition, the current study differs from previous studies of short-term IIT in that the latter have been performed mainly in Asian patients with newly diagnosed T2DM and marked hyperglycemia at baseline [e.g., mean baseline Hb A 1c ranged from 9.7 to 11.9% in previous studies (15) ]. In contrast, the current study extends the efficacy of this therapy to a multiethnic population of mainly white patients with established diabetes of mean 3-yr duration (for which 73% were on oral antidiabetic therapy) who had a mean baseline Hb A 1c of 6.8%. Coupled with an earlier demonstration of the patient acceptability of short-term IIT (24) , these data support consideration of this treatment strategy to preserve ␤-cell function early in the course of T2DM.
A limitation of this study is the single-arm design that precludes optimal assessment of any Hawthorne effect and inherent biological variability. However, our evaluation of the determinants of reversibility of ␤-cell dysfunction is not likely compromised in this regard given that 1) the capacity of short-term IIT to improve ␤-cell function has previously been well established (4 -6, 15, 17, 18, 33) and 2) we have defined reversibility by a very large improvement (Ͼ25%) over 4 wk that is unlikely to be due to Hawthorne effect or chance. It would also be of interest to compare patients treated with short-term IIT with those treated conventionally, but the current study was not designed to address this question. Another limitation is that ␤-cell function and insulin sensitivity/resistance were assessed with OGTT-based surrogate indices rather than more time-consuming and cumbersome clamp studies. However, in this context it should be recognized that ISSI-2, HOMA-IR, and the Matsuda index are all validated measurements that have been widely used in previous studies (14, 20, 21, 23, 26 -28, 30, 34) . Moreover, in concert with the clinical characterization of our study population before, during, and after IIT, these measurements have provided novel pathophysiological insight relevant to the reversal of ␤-cell dysfunction in response to IIT in early T2DM that warrants evaluation in future studies of other cohorts.
In conclusion, when administered early in the course of T2DM, short-term IIT can safely improve ␤-cell function in a well-controlled, multiethnic patient population. In one-third of the participants, this therapy improved ␤-cell function by at least 25%, accompanied by reduction of glycemia, transaminases, and insulin resistance. Most notably, decline in HOMA-IR may be a mechanism relevant to this ␤-cell functional improvement, suggesting a fundamental contribution of insulin resistance to the reversible component of ␤-cell dysfunction in early T2DM. 
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